ClinicalTrials.gg
TerminatedNCT03671590Updated Jul 19, 2024

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

A Phase 1 interventional study of TG-1701 and Umbralisib in Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by TG Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Strategic/Business Decision

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
172
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia — 31 open to participants now, 64 under way, 16 of them phase 3. Lymphoma, Non-Hodgkin · Australia.

Enrollment
61st of 147
172 · median 137
Started
2018
with 7 others
Phase 1
50 of 151
14 open now
Registered
71st of 151
by date

Among the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, this one is the 61st largest by enrollment of the 147 interventional ones that give a count, is one of 8 that started in 2018, is one of 50 in phase 1, and was the 71st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

31 of the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.

Read the detailed description

This Phase I clinical trial aims to evaluate the safety of the investigational drug TG-1701 both as a single-agent and in combination with other investigational drugs, specifically ublituximab and umbralisib. As per protocol v6.0, combination therapy (TG-1701 + Ublituximab + Umbralisib) will be discontinued and the participants from Arm 1 and 2 will be transitioned to the long-term extension period to receive TG-1701 monotherapy.

03

Conditions studied

  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed B-cell lymphoma or CLL
  • (ECOG) score of 0 to 2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with a BTK inhibitor (ibrutinib, acalabrutinib, other)
  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Known virus, virus or infection
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Arm 1: TG-1701 Monotherapy

    Participants will receive TG-1701 oral daily dose. As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.

    Drug: TG-1701

  • Experimental
    Arm 2: TG-1701 + Ublituximab + Umbralisib

    Participants will receive TG-1701, oral dose in combination with ublituximab, oral dose and umbralisib, fixed IV infusion on specific Days of Cycles 1 and 2, followed by maintenance infusions in Cycles 3 to 6 (Cycle=28 days). As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.

    Drug: TG-1701 · Drug: Umbralisib · Biological: Ublituximab

  • Experimental
    Arm 3: Long Term Safety Extension - TG-1701 Monotherapy

    All the ongoing participants from Arm 1 and 2, will be transitioned to TG-1701 monotherapy in long-term extension period, per protocol version 6.0.

    Drug: TG-1701

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose acceptable for participants

    To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities.

    Time frame: From first dose up to 30 days post last dose (Up to approximately 4.8 years)

Secondary outcomes

  1. Overall Response Rate

    To assess the overall response rate (ORR) in patients with hematologic malignancies

    Time frame: Up to approximately 4.8 years

07

Study locations

8 sites
  • TG Therapeutics Investigational Trial Site
    East Melbourne, Victoria, Australia
  • TG Therapeutics Investigational Trial Site
    Fitzroy, Victoria, Australia
  • TG Therapeutics Investigational Trial Site
    Nedlands, Western Australia, Australia
  • TG Therapeutics Investigational Trial Site
    Adelaide, Australia
  • TG Therapeutics Investigational Trial Site
    Kraków, 30-510, Poland
  • TG Therapeutics Investigational Trial Site
    Lublin, 20-090, Poland
  • TG Therapeutics Investigational Trial Site
    Warszawa, 02-781, Poland
  • TG Therapeutics Investigational Trial Site
    Wrocław, 50-367, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in May 2024, 68 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 14, 2018
StartActual
Sep 10, 2018
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03671590
Responsible party
Sponsor
First posted
Sep 14, 2018
Start date
Sep 10, 2018
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Jul 19, 2024

Study contacts

Constantine S. Tam, MD
study chair · St. Vincents Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edralbrutinib

Start the discussion